Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Oxytetracycline | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Oxytetracycline | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Oxytetracycline | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Oxytetracycline | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Oxytetracycline | hsa01522 | Endocrine resistance | 4.55E-02 | 5 | P14780, P22694, Q9UM47, P10415, Q13323 | MMP9, PRKACB, NOTCH3, BCL2, BIK | More | | Oxytetracycline | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Oxytetracycline | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Oxytetracycline | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Oxytetracycline | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | Oxytetracycline | hsa04012 | ErbB signaling pathway | 3.15E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Oxytetracycline | hsa04015 | Rap1 signaling pathway | 4.78E-02 | 5 | P09603, Q9GZP0, P11215, Q86WV1, P19174 | CSF1, PDGFD, ITGAM, SKAP1, PLCG1 | More | | Oxytetracycline | hsa04064 | NF-kappa B signaling pathway | 9.28E-03 | 10 | P10415, Q13489, P51617, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, P24522 | BCL2, BIRC3, IRAK1, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, GADD45A | More | | Oxytetracycline | hsa04071 | Sphingolipid signaling pathway | 4.78E-05 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Oxytetracycline | hsa04080 | Neuroactive ligand-receptor interaction | 4.72E-02 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1 | More | | Oxytetracycline | hsa04140 | Autophagy - animal | 4.20E-03 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Oxytetracycline | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Oxytetracycline | hsa04145 | Phagosome | 1.08E-02 | 8 | O75015, Q15080, P14598, Q13509, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, NCF1, TUBB3, MPO, TLR2, THBS4, HLA-DOB | More | | Oxytetracycline | hsa04151 | PI3K-Akt signaling pathway | 1.27E-02 | 9 | P43657, P01106, P09603, Q9GZP0, P63218, P50151, P13612, Q13751, P14784 | P2RY5, MYC, CSF1, PDGFD, GNG5, GNG10, ITGA4, LAMB3, IL2RB | More | | Oxytetracycline | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | | Oxytetracycline | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Oxytetracycline | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Oxytetracycline | hsa04612 | Antigen processing and presentation | 1.94E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Oxytetracycline | hsa04613 | Neutrophil extracellular trap formation | 1.59E-05 | 20 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Oxytetracycline | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Oxytetracycline | hsa04640 | Hematopoietic cell lineage | 4.59E-03 | 12 | P13612, P27930, P11215, P15144, P25063, P07766, P09693, P01732, P09564, P13765, P01375, P09603 | ITGA4, IL1R2, ITGAM, ANPEP, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF, CSF1 | More | | Oxytetracycline | hsa04657 | IL-17 signaling pathway | 2.59E-03 | 9 | P07900, O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Oxytetracycline | hsa04658 | Th1 and Th2 cell differentiation | 2.06E-05 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Oxytetracycline | hsa04660 | T cell receptor signaling pathway | 4.04E-05 | 12 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P20963, P09693, P01732, Q13191, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, MAPK14, GSK3B | More | | Oxytetracycline | hsa04664 | Fc epsilon RI signaling pathway | 3.15E-02 | 3 | P07948, P19174, P09917 | LYN, PLCG1, ALOX5 | More | | Oxytetracycline | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 5 | O75015, P06396, O14494, P14598, P17252 | FCGR3B, GSN, PLPP1, NCF1, PRKCA | More | | Oxytetracycline | hsa04672 | Intestinal immune network for IgA production | 1.66E-02 | 3 | P10747, P13765, P13612 | CD28, HLA-DOB, ITGA4 | More | | Oxytetracycline | hsa04924 | Renin secretion | 3.64E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Oxytetracycline | hsa04927 | Cortisol synthesis and secretion | 1.66E-02 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Oxytetracycline | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | | Oxytetracycline | hsa04940 | Type I diabetes mellitus | 2.91E-03 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Oxytetracycline | hsa04970 | Salivary secretion | 4.92E-02 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | | Oxytetracycline | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | Oxytetracycline | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | Oxytetracycline | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | | Oxytetracycline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | | Oxytetracycline | hsa05032 | Morphine addiction | 1.27E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | | Oxytetracycline | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Oxytetracycline | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | Oxytetracycline | hsa05140 | Leishmaniasis | 4.75E-04 | 9 | P13612, O75015, P14598, P13765, O60603, P01375, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, TNF, MAPK14, IRAK1, NCF4 | More | | Oxytetracycline | hsa05144 | Malaria | 4.92E-02 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | | Oxytetracycline | hsa05146 | Amoebiasis | 1.70E-03 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Oxytetracycline | hsa05150 | Staphylococcus aureus infection | 1.65E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P49913 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, CAMP | More | | Oxytetracycline | hsa05152 | Tuberculosis | 8.54E-03 | 9 | O75015, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | FCGR3B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Oxytetracycline | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Oxytetracycline | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | | Oxytetracycline | hsa05202 | Transcriptional misregulation in cancer | 2.97E-04 | 17 | Q12778, Q15532, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P22894 | MMP8 | Neutrophil collagenase | Q12778 | FOXO1 | Forkhead box protein O1 | -0.72 | P22894 | MMP8 | Neutrophil collagenase | Q15532 | SS18 | Protein SSXT | -0.867 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.9 | P14780 | MMP9 | Matrix metalloproteinase-9 | P14780 | MMP9 | Matrix metalloproteinase-9 | 1 | P22894 | MMP8 | Neutrophil collagenase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.882 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.721 | P14780 | MMP9 | Matrix metalloproteinase-9 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.851 | P22894 | MMP8 | Neutrophil collagenase | P14923 | JUP | Junction plakoglobin | -0.809 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.772 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15744 | CEBPE | CCAAT/enhancer-binding protein epsilon | 0.7 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.776 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.921 | P22894 | MMP8 | Neutrophil collagenase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.843 | P22894 | MMP8 | Neutrophil collagenase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.765 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.758 | P22894 | MMP8 | Neutrophil collagenase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.806 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.716 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P22894 | MMP8 | Neutrophil collagenase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.821 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.716 | P14780 | MMP9 | Matrix metalloproteinase-9 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.89 | P22894 | MMP8 | Neutrophil collagenase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.821 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P05164 | MPO | Myeloperoxidase | 0.909 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | P22894 | MMP8 | Neutrophil collagenase | P05164 | MPO | Myeloperoxidase | 0.905 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.882 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.858 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P08246 | ELA2 | Neutrophil elastase | 0.889 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | P22894 | MMP8 | Neutrophil collagenase | P08246 | ELA2 | Neutrophil elastase | 0.985 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.85 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.752 | P22894 | MMP8 | Neutrophil collagenase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.778 | P14780 | MMP9 | Matrix metalloproteinase-9 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.812 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P12980 | LYL1 | Protein lyl-1 | 0.702 | P14780 | MMP9 | Matrix metalloproteinase-9 | P12980 | LYL1 | Protein lyl-1 | 0.716 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.859 | P14780 | MMP9 | Matrix metalloproteinase-9 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.765 | P22894 | MMP8 | Neutrophil collagenase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.766 |
| Oxytetracycline | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Oxytetracycline | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Oxytetracycline | hsa05310 | Asthma | 2.84E-05 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Oxytetracycline | hsa05321 | Inflammatory bowel disease | 3.13E-07 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Oxytetracycline | hsa05322 | Systemic lupus erythematosus | 1.24E-04 | 13 | O75015, P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | FCGR3B, ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Oxytetracycline | hsa05323 | Rheumatoid arthritis | 1.58E-02 | 5 | P01375, P13765, P10747, P09341, O60603 | TNF, HLA-DOB, CD28, CXCL1, TLR2 | More | | Oxytetracycline | hsa05332 | Graft-versus-host disease | 1.09E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Oxytetracycline | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | | |